An observational study of survival in patients with chronic-phase chronic myeloid leukemia (CML-CP) after 1, 3, and 5 years of tyrosine kinase inhibitor (TKI) therapy (SIMPLICITY) Meeting Abstract


Authors: Michallet, M.; Cortes, J.; Gambacorti-Passerini, C.; Hehlmann, R.; Williams, L. A.; Goldberg, S. L.; Davis, C.; De Solda, F.; Sen, G. P.; Gajavelli, S.; Mauro, M. J.
Abstract Title: An observational study of survival in patients with chronic-phase chronic myeloid leukemia (CML-CP) after 1, 3, and 5 years of tyrosine kinase inhibitor (TKI) therapy (SIMPLICITY)
Meeting Title: 6th Annual Meeting of the Society of Hematologic Oncology (SOHO 2018)
Keywords: survival; chronic myeloid leukemia; tyrosine kinase inhibitor; deaths
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 18
Issue: Suppl. 1
Meeting Dates: 2018 Sep 12-15
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2018-09-01
Start Page: S229
Language: English
ACCESSION: WOS:000444343400155
DOI: 10.1016/j.clml.2018.07.105
PROVIDER: wos
Notes: Meeting Abstract: CML-264 -- Source: Wos
Altmetric Score
MSK Authors
  1. Michael John Mauro
    134 Mauro